{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:51:49Z","timestamp":1792007509865,"version":"4.4.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T00:00:00Z","timestamp":1706572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T00:00:00Z","timestamp":1706572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Innovation of Science and Technology, Fujian Province","award":["2021Y9134"],"award-info":[{"award-number":["2021Y9134"]}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2022J01213"],"award-info":[{"award-number":["2022J01213"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2020J01120429"],"award-info":[{"award-number":["2020J01120429"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2022J02036"],"award-info":[{"award-number":["2022J02036"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s00259-024-06621-0","type":"journal-article","created":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T03:02:35Z","timestamp":1706583755000},"page":"1926-1936","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["[68Ga]Pentixafor PET\/CT for staging and prognostic assessment of newly diagnosed multiple myeloma: comparison to [18F]FDG PET\/CT"],"prefix":"10.1007","volume":"51","author":[{"given":"Zhenying","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aihong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinfeng","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibing","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,30]]},"reference":[{"key":"6621_CR1","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/s0140-6736(21)00135-5","volume":"397","author":"N van de Donk","year":"2021","unstructured":"van de Donk N, Pawlyn C, Yong K. Multiple myeloma. Lancet (London, England). 2021;397:410\u201327. https:\/\/doi.org\/10.1016\/s0140-6736(21)00135-5.","journal-title":"Lancet (London, England)"},{"key":"6621_CR2","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/sj.thj.6200312","volume":"4","author":"B Durie","year":"2003","unstructured":"Durie B, Kyle R, Belch A, Bensinger W, Blade J, Boccadoro M, et al. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J. 2003;4:379\u201398. https:\/\/doi.org\/10.1038\/sj.thj.6200312.","journal-title":"Hematol J"},{"key":"6621_CR3","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/jco.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst H, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33:2863\u20139. https:\/\/doi.org\/10.1200\/jco.2015.61.2267.","journal-title":"J Clin Oncol"},{"key":"6621_CR4","doi-asserted-by":"publisher","first-page":"593","DOI":"10.3324\/haematol.2016.145078","volume":"102","author":"E Kastritis","year":"2017","unstructured":"Kastritis E, Terpos E, Roussou M, Gavriatopoulou M, Migkou M, Eleutherakis-Papaiakovou E, et al. Evaluation of the revised international staging system in an independent cohort of unselected patients with multiple myeloma. Haematologica. 2017;102:593\u20139. https:\/\/doi.org\/10.3324\/haematol.2016.145078.","journal-title":"Haematologica"},{"key":"6621_CR5","first-page":"513","volume":"7","author":"R Bataille","year":"1987","unstructured":"Bataille R, Grenier J, Sany J. Unexpected normal serum beta-microglobulin (B2M) levels in multiple myeloma. Anticancer Res. 1987;7:513\u20135.","journal-title":"Anticancer Res"},{"key":"6621_CR6","doi-asserted-by":"publisher","first-page":"854","DOI":"10.2214\/ajr.13.10724","volume":"203","author":"M D'Anastasi","year":"2014","unstructured":"D\u2019Anastasi M, Notohamiprodjo M, Schmidt G, D\u00fcrr H, Reiser M, Baur-Melnyk A. Tumor load in patients with multiple myeloma: \u03b22-microglobulin levels versus whole-body MRI. AJR Am J Roentgenol. 2014;203:854\u201362. https:\/\/doi.org\/10.2214\/ajr.13.10724.","journal-title":"AJR Am J Roentgenol"},{"key":"6621_CR7","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.ejca.2005.11.037","volume":"42","author":"B Durie","year":"2006","unstructured":"Durie B. The role of anatomic and functional staging in myeloma: description of Durie\/Salmon plus staging system. Eur J Cancer (Oxford, England: 1990). 2006;42:1539\u201343. https:\/\/doi.org\/10.1016\/j.ejca.2005.11.037.","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"key":"6621_CR8","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1002\/cncr.10818","volume":"95","author":"A Baur","year":"2002","unstructured":"Baur A, St\u00e4bler A, Nagel D, Lamerz R, Bartl R, Hiller E, et al. Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon? Cancer. 2002;95:1334\u201345. https:\/\/doi.org\/10.1002\/cncr.10818.","journal-title":"Cancer"},{"key":"6621_CR9","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00256-021-03841-5","volume":"51","author":"F Lecouvet","year":"2022","unstructured":"Lecouvet F, Vekemans M, Van Den Berghe T, Verstraete K, Kirchgesner T, Acid S, et al. Imaging of treatment response and minimal residual disease in multiple myeloma: state of the art WB-MRI and PET\/CT. Skeletal Radiol. 2022;51:59\u201380. https:\/\/doi.org\/10.1007\/s00256-021-03841-5.","journal-title":"Skeletal Radiol"},{"key":"6621_CR10","doi-asserted-by":"publisher","first-page":"e1198","DOI":"10.1259\/bjr\/52759767","volume":"85","author":"C Messiou","year":"2012","unstructured":"Messiou C, Giles S, Collins D, West S, Davies F, Morgan G, et al. Assessing response of myeloma bone disease with diffusion-weighted MRI. Br J Radiol. 2012;85:e1198\u2013203. https:\/\/doi.org\/10.1259\/bjr\/52759767.","journal-title":"Br J Radiol"},{"key":"6621_CR11","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1148\/radiol.2017170281","volume":"286","author":"A Kosmala","year":"2018","unstructured":"Kosmala A, Weng A, Heidemeier A, Krauss B, Knop S, Bley T, et al. Multiple myeloma and dual-energy CT: diagnostic accuracy of virtual noncalcium technique for detection of bone marrow infiltration of the spine and pelvis. Radiology. 2018;286:205\u201313. https:\/\/doi.org\/10.1148\/radiol.2017170281.","journal-title":"Radiology"},{"key":"6621_CR12","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1001\/jama.290.24.3199","volume":"290","author":"G Antoch","year":"2003","unstructured":"Antoch G, Vogt F, Freudenberg L, Nazaradeh F, Goehde S, Barkhausen J, et al. Whole-body dual-modality PET\/CT and whole-body MRI for tumor staging in oncology. JAMA. 2003;290:3199\u2013206. https:\/\/doi.org\/10.1001\/jama.290.24.3199.","journal-title":"JAMA"},{"key":"6621_CR13","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1148\/rg.2019180096","volume":"39","author":"A Ormond Filho","year":"2019","unstructured":"Ormond Filho A, Carneiro B, Pastore D, Silva I, Yamashita S, Consolo F, et al. Whole-body imaging of multiple myeloma: diagnostic criteria. Radiographics. 2019;39:1077\u201397. https:\/\/doi.org\/10.1148\/rg.2019180096.","journal-title":"Radiographics"},{"key":"6621_CR14","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.critrevonc.2018.02.012","volume":"124","author":"J Gariani","year":"2018","unstructured":"Gariani J, Westerland O, Natas S, Verma H, Cook G, Goh V. Comparison of whole body magnetic resonance imaging (WBMRI) to whole body computed tomography (WBCT) or 18F-fluorodeoxyglucose positron emission tomography\/CT (18F-FDG PET\/CT) in patients with myeloma: systematic review of diagnostic performance. Crit Rev Oncol Hematol. 2018;124:66\u201372. https:\/\/doi.org\/10.1016\/j.critrevonc.2018.02.012.","journal-title":"Crit Rev Oncol Hematol"},{"key":"6621_CR15","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/blood-2017-03-774422","volume":"130","author":"L Rasche","year":"2017","unstructured":"Rasche L, Angtuaco E, McDonald J, Buros A, Stein C, Pawlyn C, et al. Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. Blood. 2017;130:30\u20134. https:\/\/doi.org\/10.1182\/blood-2017-03-774422.","journal-title":"Blood"},{"key":"6621_CR16","doi-asserted-by":"publisher","first-page":"e206","DOI":"10.1016\/s1470-2045(17)30189-4","volume":"18","author":"M Cavo","year":"2017","unstructured":"Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, et al. Role of 18F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017;18:e206\u201317. https:\/\/doi.org\/10.1016\/s1470-2045(17)30189-4.","journal-title":"Lancet Oncol"},{"key":"6621_CR17","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.leukres.2013.06.002","volume":"37","author":"L Bao","year":"2013","unstructured":"Bao L, Lai Y, Liu Y, Qin Y, Zhao X, Lu X, et al. CXCR4 is a good survival prognostic indicator in multiple myeloma patients. Leuk Res. 2013;37:1083\u20138. https:\/\/doi.org\/10.1016\/j.leukres.2013.06.002.","journal-title":"Leuk Res"},{"key":"6621_CR18","doi-asserted-by":"publisher","first-page":"205","DOI":"10.7150\/thno.16576","volume":"7","author":"C Lapa","year":"2017","unstructured":"Lapa C, Schreder M, Schirbel A, Samnick S, Kort\u00fcm K, Herrmann K, et al. [68Ga]Pentixafor-PET\/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - comparison to [18F]FDG and laboratory values. Theranostics. 2017;7:205\u201312. https:\/\/doi.org\/10.7150\/thno.16576.","journal-title":"Theranostics"},{"key":"6621_CR19","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s00259-019-04605-z","volume":"47","author":"Q Pan","year":"2020","unstructured":"Pan Q, Cao X, Luo Y, Li J, Feng J, Li F. Chemokine receptor-4 targeted PET\/CT with 68Ga-Pentixafor in assessment of newly diagnosed multiple myeloma: comparison to 18F-FDG PET\/CT. Eur J Nucl Med Mol Imaging. 2020;47:537\u201346. https:\/\/doi.org\/10.1007\/s00259-019-04605-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6621_CR20","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s12149-021-01652-1","volume":"35","author":"S Kuyumcu","year":"2021","unstructured":"Kuyumcu S, Isik E, Tiryaki T, Has-Simsek D, Sanli Y, Buyukkaya F, et al. Prognostic significance of 68Ga-pentixafor PET\/CT in multiple myeloma recurrence: a comparison to 18F-FDG PET\/CT and laboratory results. Ann Nucl Med. 2021;35:1147\u201356. https:\/\/doi.org\/10.1007\/s12149-021-01652-1.","journal-title":"Ann Nucl Med"},{"key":"6621_CR21","doi-asserted-by":"publisher","first-page":"20211272","DOI":"10.1259\/bjr.20211272","volume":"95","author":"A Shekhawat","year":"2022","unstructured":"Shekhawat A, Singh B, Malhotra P, Watts A, Basher R, Kaur H, et al. Imaging CXCR4 receptors expression for staging multiple myeloma by using 68Ga-pentixafor PET\/CT: comparison with 18F-FDG PET\/CT. Br J Radiol. 2022;95:20211272. https:\/\/doi.org\/10.1259\/bjr.20211272.","journal-title":"Br J Radiol"},{"key":"6621_CR22","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/s1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson K, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u201346. https:\/\/doi.org\/10.1016\/s1470-2045(16)30206-6.","journal-title":"Lancet Oncol"},{"key":"6621_CR23","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1007\/s11307-021-01664-3","volume":"24","author":"Z Chen","year":"2022","unstructured":"Chen Z, Yang A, Zhang J, Chen A, Zhang Y, Huang C, et al. CXCR4-directed PET\/CT with [68Ga]pentixafor in central nervous system lymphoma: a comparison with [18F]FDG PET\/CT. Mol Imaging Biol. 2022;24:416\u201324. https:\/\/doi.org\/10.1007\/s11307-021-01664-3.","journal-title":"Mol Imaging Biol"},{"key":"6621_CR24","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41408-018-0124-1","volume":"8","author":"L Moulopoulos","year":"2018","unstructured":"Moulopoulos L, Koutoulidis V, Hillengass J, Zamagni E, Aquerreta J, Roche C, et al. Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group. Blood cancer J. 2018;8:95. https:\/\/doi.org\/10.1038\/s41408-018-0124-1.","journal-title":"Blood cancer J"},{"key":"6621_CR25","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1148\/radiol.10091809","volume":"257","author":"K Fechtner","year":"2010","unstructured":"Fechtner K, Hillengass J, Delorme S, Heiss C, Neben K, Goldschmidt H, et al. Staging monoclonal plasma cell disease: comparison of the Durie-Salmon and the Durie-Salmon PLUS staging systems. Radiology. 2010;257:195\u2013204. https:\/\/doi.org\/10.1148\/radiol.10091809.","journal-title":"Radiology"},{"key":"6621_CR26","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1007\/s00259-017-3909-8","volume":"45","author":"C Nanni","year":"2018","unstructured":"Nanni C, Versari A, Chauvie S, Bertone E, Bianchi A, Rensi M, et al. Interpretation criteria for FDG PET\/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe). Eur J Nucl Med Mol Imaging. 2018;45:712\u20139. https:\/\/doi.org\/10.1007\/s00259-017-3909-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6621_CR27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3892\/mco.2020.2039","volume":"13","author":"T Wang","year":"2020","unstructured":"Wang T, Peng X, Qiao W, Xing Y, Yang J, Zhao J. The role of CT in PET\/CT for assessing diffuse infiltration of bone marrow in multiple myeloma using the Durie-Salmon PLUS staging system. Mol Clin Oncol. 2020;13:13\u20138. https:\/\/doi.org\/10.3892\/mco.2020.2039.","journal-title":"Mol Clin Oncol"},{"key":"6621_CR28","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/ejh.13356","volume":"104","author":"V Pfahler","year":"2020","unstructured":"Pfahler V, D\u2019Anastasi M, D\u00fcrr H, Schinner R, Ricke J, Baur-Melnyk A. Tumor load in patients with multiple myeloma: \u03b22-microglobulin levels versus low-dose whole-body CT. Eur J Haematol. 2020;104:383\u20139. https:\/\/doi.org\/10.1111\/ejh.13356.","journal-title":"Eur J Haematol"},{"key":"6621_CR29","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s11899-021-00633-5","volume":"16","author":"L Bertamini","year":"2021","unstructured":"Bertamini L, D\u2019Agostino M, Gay F. MRD assessment in multiple myeloma: progress and challenges. Curr Hematol Malig Rep. 2021;16:162\u201371. https:\/\/doi.org\/10.1007\/s11899-021-00633-5.","journal-title":"Curr Hematol Malig Rep"},{"key":"6621_CR30","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3389\/fmed.2019.00069","volume":"6","author":"B Jamet","year":"2019","unstructured":"Jamet B, Bailly C, Carlier T, Touzeau C, Nanni C, Zamagni E, et al. Interest of pet imaging in multiple myeloma. Front Med (Lausanne). 2019;6:69. https:\/\/doi.org\/10.3389\/fmed.2019.00069.","journal-title":"Front Med (Lausanne)"},{"key":"6621_CR31","doi-asserted-by":"publisher","first-page":"4198673","DOI":"10.1155\/2018\/4198673","volume":"2018","author":"S Deng","year":"2018","unstructured":"Deng S, Zhang B, Zhou Y, Xu X, Li J, Sang S, et al. The Role of 18F-FDG PET\/CT in Multiple myeloma staging according to IMPeTUs: comparison of the Durie-Salmon Plus and Other Staging Systems. Contrast Media Mol Imaging. 2018;2018:4198673. https:\/\/doi.org\/10.1155\/2018\/4198673.","journal-title":"Contrast Media Mol Imaging"},{"key":"6621_CR32","doi-asserted-by":"publisher","first-page":"152","DOI":"10.2214\/ajr.16.17219","volume":"209","author":"G Filonzi","year":"2017","unstructured":"Filonzi G, Mancuso K, Zamagni E, Nanni C, Spinnato P, Cavo M, et al. A comparison of different staging systems for multiple myeloma: can the MRI pattern play a prognostic role? AJR Am J Roentgenol. 2017;209:152\u20138. https:\/\/doi.org\/10.2214\/ajr.16.17219.","journal-title":"AJR Am J Roentgenol"},{"key":"6621_CR33","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00259-018-4114-0","volume":"46","author":"S Jung","year":"2019","unstructured":"Jung S, Kwon S, Min J, Bom H, Ahn S, Jung S, et al. 18F-FDG PET\/CT is useful for determining survival outcomes of patients with multiple myeloma classified as stage II and III with the Revised International Staging System. Eur J Nucl Med Mol Imaging. 2019;46:107\u201315. https:\/\/doi.org\/10.1007\/s00259-018-4114-0.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06621-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-024-06621-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06621-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T10:03:09Z","timestamp":1717063389000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-024-06621-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,30]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["6621"],"URL":"https:\/\/doi.org\/10.1007\/s00259-024-06621-0","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,30]]},"assertion":[{"value":"5 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures involving human participants were carried out in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This article does not contain any experiments with animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}